Dr. Susan Galbraith

Well, I would just say I was delighted with the overall presence that we had at the ESMO meeting.

The ESMO meeting is getting larger and very impactful data that was presented there.

You know, what we...

we're able to show that as well as progression in our early portfolio is very importantly, multiple datasets that showed that we're actually delivering against this vision that antibody drug conjugates can improve on and therefore displace chemotherapy from different indications, but also that we can move those into the earlier lines of therapy where the opportunity for improving the potential for cure is the highest.

So it was a great meeting.

It was very exciting to see the data being presented.

Yes, I do.

I mean, hormone receptor positive is the biggest segment of breast cancer, you know, with about 65, 70% of patients.

HER2 positive is 15 to 20% of patients, it's classically defined.

And then the terminology I don't particularly like is triple negative breast cancer, which defines what, you know, what the cancer isn't.

It's not hormone receptor positive and it's not got HER2 positivity.

But in that group of patients, it's really difficult to treat.

It is the heterogeneous patient population, the triple negative.

But yes, you're right.

Those are the three main groups.

Yeah.

So as you rightly point out, Destiny Breast 03 was in the second line metastatic patients.

So patients have already progressed outside of the breast.

That was the second line.

And that showed an improvement over previous standard of care, previous antibody drug conjugates, trastuzumab DM1.